News
-
Iranian Blood Transfusion Organization (IBTO) Newsletter – November 2019
The latest issue from the Iranian Blood Transfusion Organization’s (IBTO) newsletter is now available on TIF’s website!
Read More » -
-
Thalassaemia Month of Banyumas 2019 -“Banyumas Goes to Zero Growth of Thalassaemia 2023”
Written by Dinar Faiza (edited) The Indonesian Thalassemia Foundation of Banyumas and the Banyumas District Government organised and launched, from November 1 to November 30, 2019, a massive pilot…
Read More » -
The Emirates Thalassaemia Society launches the 12th edition of the ”What is Thalassaemia?”competition
The Emirates Thalassemia Society (ETS), a prominent TIF’s Member, in collaboration with the United Arab Emirates’ Ministry of Education, is organising the 12th Season of the ”What is Thalassemia?”…
Read More » -
Global Blood Therapeutics & Syros Pharma team up on novel therapies for β-thalassaemia & SCD
Global Blood Therapeutics (GBT) and Syros Pharma announced yesterday their partnership to discover, develop and commercialize novel therapies for SickleCell Disease (SCD) and β-thalassaemia. Under the agreement, Syros will use…
Read More » -
TIF organises the‘’1st International Informational Forum on New & Innovative Therapies for Haemoglobinopathies’’_12 December 2019
In light of the rapid scientific developments in the field of thalassaemia and Sickle Cell Disease (SCD) – new drugs and gene therapies – which promise to change the…
Read More » -
TIF by the side of thalassaemia patients in Syria
The World Health Organisation (WHO) has contacted the Thalassaemia International Federation (TIF) to request the provision of its expertise and technical support on the thalassaemia care and management of…
Read More » -
TIF will coordinate efforts for patients’ information on Reblozyl in 62 countries
A new and encouraging chapter is finally opening up for patients with thalassaemia, following the recent approval of the US Food and Drug Administration (FDA) to market the drug Reblozyl,…
Read More » -
ASH ANNUAL MEETING | 7-10 December 2019
Celgene Corporation, Acceleron Pharma, Sangamo Therapeutics & Agios Pharmaceuticals are expected to present new and updated data on the progress of key ongoing therapies for thalassaemia and sickle cell…
Read More » -
Deferasirox Mylan: A new generic drug for the treatment of iron overload in β-thalassaemia major obtained approval by the EMA
The European Medicines Agency’s (EMA) has recently granted marketing authorisation for the medicinal product ”Deferasirox Mylan”, intended for the treatment of chronic iron overload due to blood transfusions in patients with…
Read More »